Insights into the Management of Overactive Bladder: What Difference Can Mirabegron Make?

Journal Title: Journal of Urological Surgery - Year 2019, Vol 6, Issue 2

Abstract

Oral pharmacotherapy constitutes second-line treatment for overactive bladder (OAB) after lifestyle modifications, bladder retraining, and pelvic floor muscle exercises. Antimuscarinics have an established role in the treatment of OAB. However, antimuscarinics are known to have low persistence rates in clinical practice. Mirabegron is an oral β3-adrenoreceptor agonist which has emerged as an alternative to antimuscarinics for managing OAB. Overall, mirabegron has similar clinical efficacy to antimuscarinics and is superior to placebo. Mirabegron has been generally well tolerated in both interventional and non-interventional studies. Persistence has been shown to be higher with mirabegron than with antimuscarinics in realworld studies. Increased blood pressure is associated with mirabegron and therefore its use is contraindicated in patients with severe uncontrolled hypertension. However, a low rate of treatment cessation due to cardiovascular issues has been noted in clinical trials. Mirabegron’s utility in the elderly patient population has been well supported with promising efficacy and safety outcomes. New data from a prospective placebo-controlled randomized trial in older OAB patients is expected to be published soon. Mirabegron does not interfere with detrusor contractions during the emptying phase of the micturition cycle and hence lacks any significant effect on post-void residual volume. Mirabegron can be combined with antimuscarinics to synergize clinical effectiveness. Overall, mirabegron represents a well-tolerated and effective medical treatment option for OAB. Mirabegron could be used as an alternative to antimuscarinics, especially in patients who do not improve with antimuscarinics and/or experience bothersome side effects for whom anticholinergic load may be a relevant consideration.

Authors and Affiliations

Ömer Acar, Mustafa Levent Erton, Tufan Tarcan

Keywords

Related Articles

Are Haematological Parameters Reliable for Differential Diagnosis of Testicular Torsion and Epididymitis?

Objective: Acute scrotum is a urological emergency that can result in loss of the testis if the differential diagnosis is not made immediately. Testicular torsion (TT) and epididymo-orchitis (EO) are the two most common...

Predictive Value of Ureteral Jet Dynamics to Differentiate Postrenal Obstruction After Renal Transplantation: A Prospective Cohort Study

Objective: This study aimed to prospectively investigate the predictive value of ureteral jet dynamics measured by Doppler ultrasonography (D-US) to differentiate postrenal obstruction from other reasons after double-J s...

Primary Urothelial Carcinoma of the Anterior Urethra

We report the case of an 89-year-old male with an isolated anterior urethral invasive urothelial carcinoma. This is a rare primary tumour of the anterior urethra, as this area is not lined by urothelium. It was managed w...

Download PDF file
  • EP ID EP48971
  • DOI 10.4274/jus.galenos.2019.2533
  • Views 379
  • Downloads 0

How To Cite

Ömer Acar, Mustafa Levent Erton, Tufan Tarcan (2019). Insights into the Management of Overactive Bladder: What Difference Can Mirabegron Make?. Journal of Urological Surgery, 6(2), -. https://europub.co.uk/articles/-A-48971